Loading
A phase 1/2 trial of SYS6045 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., active and no longer recruiting.
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07122063 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 266 participants enrolled, started 2025-08-11 and due to reach its primary completion in 2027-07-30. Interventions recorded: SYS6045.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/